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llen Pinnow, MS,* Daniel Canos, MPH,* Lowell F. Satler, MD,* Kenneth M. Kent, MD, PHD,*
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OBJECTIVES The aim of this study was to establish safety and feasibility of oral Rapamycin at two doses—2
mg and 5 mg—in achieving low rates of repeat target lesion revascularization (TLR) in de
novo native coronary artery lesions.
BACKGROUND Drug-eluting stents have shown the ability to limit restenosis. Oral Rapamycin is an
alternative strategy that can target multiple coronary lesions suitable for treatment with any
approved metal stent and at potentially lower cost.
METHODS The Oral Rapamune to Inhibit Restenosis (ORBIT) study is an open-label study of 60
patients with de novo lesions treated with bare metal stents in up to two vessels. After a
loading dose of 5 mg, patients received a daily dose of 2 mg (n  30) and 5 mg (n  30) for
30 days. Six-month angiographic, intravascular ultrasound (IVUS), and clinical follow-up
were conducted.
RESULTS Baseline clinical and procedural characteristics were similar: 10% of patients in the 2-mg
group and 30% in the 5-mg group did not complete the course; 43% in the 2-mg group and
66% in the 5-mg group had side effects. At six-month follow-up, late loss (0.6  0.5 mm vs.
0.7  0.5 mm; p  NS), in-stent binary restenosis (7.1% vs. 6.9%; p  NS), in-stent percent
volume obstruction by IVUS (29% vs. 24%; p  NS), and clinically driven TLR (14.3% vs.
6.9%; p  NS) were similar in 2-mg and 5-mg groups.
CONCLUSIONS Oral Rapamycin for the prevention of restenosis is safe, feasible, and associated with low rates
of repeat revascularization. Although associated with certain side effects, it may be considered
for patients undergoing multivessel stents if proven in larger randomized studies. (J Am
Coll Cardiol 2004;44:1386–92) © 2004 by the American College of Cardiology Foundatione
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(hile coronary stenting has become standard of care for
ercutaneous interventions (PCIs), in-stent restenosis has
ersisted as a major obstacle. The prevention of restenosis
as focused on inhibition of smooth muscle cell (SMC)
ivision. The development of drug-eluting stents has al-
owed stents to be used as vehicles for prolonged and
ufficient intramural drug delivery. Clinical efficacy and
afety have been established for simple lesion morphologies
sing the Rapamycin-eluting stent (Cypher, Cordis, Miami,
lorida), which incorporates a Rapamycin polymer onto
are metal (1–7). However, as the drug-eluting stent tech-
ology is limited to a stent platform, it may cause vessel
oxicity with the potential development of aneurysms, edge
ffect, thrombosis, and stent malapposition (8–10). Al-
hough clinical results are encouraging, this technology,
hen applied to multivessel disease, is expensive and not
From the *Cardiovascular Research Institute, Washington Hospital Center,
ashington, DC; and the †Royal Melbourne Hospital and NHMRC Centre of
linical Research Excellence in Therapeutics, Department of Epidemiology and
reventive Medicine, Monash University, Melbourne, Australia.
Manuscript received April 6, 2004; revised manuscript received May 25, 2004,ccepted June 22, 2004.conomically sustainable. Rapamycin (sirolimus) is a natural
acrocyclic lactone with potent immunosuppressive and
nti-proliferative activity that was approved by the Food and
rug Administration in 1999 for prophylaxis against renal
ransplant rejection (11–17).
A number of preclinical studies support the use of
ystemic administration of Rapamycin in reducing SMC
rowth, the mediator of neointimal proliferation (18–22).
reclinical studies have demonstrated reduction of neoin-
ima formation after balloon injury in the porcine and the
abbit models of restenosis with the use of Rapamycin (18)
nd its analogue everolimus (Novartis Pharmaceuticals
orp., East Hanover, New Jersey) (19).
Oral Rapamycin is an alternative delivery strategy that
an target multiple coronary lesions that are targets for
atheter-based revascularization with any approved metal
tent and with potentially lower cost. The aim of this pilot
tudy was to establish the safety and feasibility of oral
apamycin at two dosing strategies (2 and 5 mg) in
chieving low rates of repeat target lesion revascularization
TLR) in de novo native coronary artery lesions.
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October 6, 2004:1386–92 Results of the ORBIT Pilot StudyETHODS
his clinical trial was sponsored by the Medlantic Research
nstitute at Washington Hospital Center, Washington, DC.
he study was approved by the institutional review board and
onitored by an independent reviewer. A written informed
onsent was obtained from all patients before the study drug
as administered. A clinical events committee independently
djudicated all clinical events in a blinded fashion.
atient population. Oral Rapamune to Inhibit Restenosis
ORBIT) is an open-label study of 60 patients with de novo
oronary artery stenosis treated with stent implantation in
p to two vessels. Patients were enrolled between October
001 and November 2002. The first 30 patients (49 lesions)
eceived rapamycin 2 mg/day for 30 days, and the second 30
atients (37 lesions) received rapamycin 5 mg/day for 30
ays. The loading dose for both regimens was 5 mg given
ither immediately before or after the intervention. Angio-
raphic and clinical follow-up were performed at six
onths.
Inclusion criteria were age 18 years, stable or unstable
ngina with evidence of ischemia, treatment of de novo
esions in 2 coronary arteries, target lesion 2.5 to 4.0 mm
n diameter, target lesion 15 to 30 mm in length (visual
stimate), left ventricular ejection fraction 20%, and con-
ition of patient as being an acceptable candidate for
oronary artery bypass graft surgery (CABG).
Exclusion criteria were unprotected left main stenosis,
stial target lesion, in-stent restenotic lesion or prior stent
ithin 5 mm of target lesion, angiographic evidence of
hrombus, totally occluded vessel (Thrombolysis In Myo-
ardial Infarction level 0), impaired renal function (creati-
ine 2.5 mg/dl), hemodynamic instability (hypotension),
ifurcation lesions, excess co-morbid illness, contraindica-
ions (i.e., allergy) for drug treatments, active peptic ulcer or
pper gastrointestinal bleeding, and status of patient as
urrently being treated with immunosuppressant therapy.
tudy definitions. Q-wave myocardial infarction (MI) was
efined by the presence of new pathologic Q waves on the
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
IVUS  intravascular ultrasound
MI  myocardial infarction
MLD  minimal luminal diameter
ORAR  Oral Rapamycin to Prevent Restenosis in
Patients Undergoing Coronary Stent Therapy
trial
ORBIT  Oral Rapamune to Inhibit Restenosis study
OSIRIS  Oral Sirolimus to Inhibit Recurrent In-stent
Stenosis trial
PCI  percutaneous coronary intervention
QCA  quantitative coronary angiography
SMC  smooth muscle cell
TLR  target lesion revascularization
TVR  target vessel revascularizationlectrocardiogram associated with an elevation of total preatinine kinase elevation at least 2 times the upper normal
alues. Non–Q-wave MI was defined as a total creatinine
inase elevation 2 times normal, with an elevation of MB
soenzyme of at least 3 times the upper normal value
ithout new Q waves. Angiographic binary restenosis at
ollow-up was defined as 50% diameter narrowing within
he stent and in the segment including the stent plus its
dges (within 5 mm). Measurements were performed of the
eference vessel, the stented segment, and the lesion seg-
ent including the edges of the stent. A lumen diameter of
mm was imputed in the presence of a total occlusion at
aseline or at follow-up. Acute gain (in mm) was defined as
he change in the stent minimum luminal diameter (MLD)
rom baseline to the final procedural angiogram. Late loss
in mm) was defined as the change in stent MLD from the
nal to the follow-up angiogram, and the arithmetic loss
ndex within the stent was defined as late loss/acute gain.
eucopenia was defined as white cell count below 3 109/l.
tudy end points. The primary end point of this study was
ngiographic restenosis at six months after procedure. Sec-
ndary end points included TLR, target vessel revascular-
zation (TVR), and composite major adverse cardiac events
death, MI [Q-wave and non–Q-wave], CABG, or repeat
LR) at six months after procedure and intravascular
ltrasound (IVUS) end points including percent of stent
olume obstruction (neointima). A drug safety profile was
onducted, and adverse reactions were adjudicated and
ecorded.
Quantitative coronary angiography (QCA) was per-
ormed to assess in-stent and in-lesion MLD and late
umen loss at six months after the procedure using the
MS-GFT system (Medis, Leiden, the Netherlands). The
CA was performed before the procedure, after the proce-
ure, and for the six-month follow-up angiogram.
Intravascular ultrasound studies were performed after
ntracoronary administration of 200 g of nitroglycerin with
ommercially available IVUS system (Boston Scientific
orp./Scimed, Natick, Massachusetts). The IVUS catheter
as advanced distal to the lesion, and imaging was per-
ormed retrograde, back to the proximal reference at an
utomatic transducer pullback speed of 0.5 mm/s. Quanti-
ative volumetric IVUS analysis was performed in an inde-
endent core laboratory. With the use of computerized
lanimetry software (TapeMeasure, INDEC Systems Inc.,
apitola, California), stent and reference segments were
easured every 1 mm. Reference segment external elastic
embrane (EEM), lumen, and plaque and media (EEM-
umen) areas were measured over a 10-mm length adjacent
o stent edge. Stent, lumen, and intimal hyperplasia (stent-
umen) areas were measured every 1 mm within the stented
egment, and volumes were calculated using Simpson’s rule.
ntimal hyperplasia volumes were corrected for stent length
y dividing intimal hyperplasia by stent length.
tatistical analysis. Continuous variables were expressed
s mean  SD, and categorical data were expressed as
ercentages. Continuous variables were compared using
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Results of the ORBIT Pilot Study October 6, 2004:1386–92tudent t test, and categorical variables were compared
sing chi-square statistics or Fisher exact test. Analyses on
ariables containing non-independent observations were
nalyzed using the SAS GENMOD procedure. All analyses
ere performed by intent to treat. A p value of 0.05 was
onsidered statistically significant.
ESULTS
haracteristics of study population. The two cohorts of 2
nd 5 mg Rapamycin were matched for baseline clinical and
rocedural characteristics (Table 1). Patients treated with 5
g Rapamycin compared with the 2 mg cohort had a lower
umber of diseased vessels (1.4  0.6 mm vs. 1.9  0.7; p
0.01) and had less lesions treated overall. The coronary
esions were evenly distributed in the native coronary
ystem. Lesion length (14.1  6.8 mm vs. 13.6  4.8 mm;
 NS) and reference vessel diameter (3.0  0.4 mm vs.
.1  0.5 mm; p  NS) were similar in the 2- and 5-mg
roups. The predominant interventional approach to treat-
ent was direct stenting in both cohorts (48% overall).
n-hospital outcomes. No in-hospital deaths or Q-wave
Table 1. Baseline Clinical, Lesion, and Proced
Rap
n 
Age, yrs (mean  SD) 5
Number of males, n (%)
Smoking history, n (%)
History of cerebrovascular disease, n (%)
History of diabetes, n (%)
Oral hypoglycemic therapy, n (%)
Insulin-requiring, n (%)
Hypertension, n (%)
Hyperlipidemia, n (%)
Prior cardiac bypass graft surgery, n (%)
Prior myocardial infarction, n (%)
Prior PCI, n (%)
Unstable angina, n (%)
CCS* III or IV, n (%)
Left ventricular ejection fraction 0
Number of diseased vessels
Single, n (%)
Two, n (%)
Three, n (%)
Number of diseased vessels 1
Lesion Characteristics n 
Left anterior descending, n (%)
Circumflex, n (%)
Right coronary artery, n (%)
Lesion length, mm 14
Reference vessel diameter, mm 3
Procedural strategy, n (%)
Stents per patient
Atherectomy, n (%)
Direct stenting, n (%)
Pre-balloon, n (%)
Cutting balloon, n (%)
*Data for one patient was not entered on this question.
CCS  Canadian Cardiovascular Society angina class; PIs occurred in either cohort. Three patients in the 2-mg d10.0%) and two patients in the 5-mg (6.7%) Rapamycin
roups sustained non–Q-wave MIs. There were no reported
brupt closures, and no patients needed emergent CABG or
epeat in-hospital PCI.
ngiographic and IVUS results. Six-month angiographic
nalysis was performed in 86% of lesions (42 of 49) in the
-mg Rapamycin cohort and 78% of lesions (29 of 37) in
he 5-mg Rapamycin cohort (Table 2). The MLD at
ollow-up (2.3  0.6 mm vs. 2.3  0.8 mm; p  NS) and
ate loss (0.6 0.6 mm vs. 0.7 0.5 mm; pNS) were not
ignificantly different in the two groups—indicating no
ose-response effect.
Intravascular ultrasound analysis was performed in 68%
f lesions (32 of 47) in the 2-mg Rapamycin cohort and
3% of lesions (16 of 37) in the 5-mg Rapamycin cohort.
o dose response effect was seen within the 2- and 5-mg
ohorts with similar six-month intimal hyperplasia volume
orrected for stent length (2.35 1.31 mm3 vs. 2.16 1.42
m3; p  NS) and percent volume obstruction (29% vs.
4%; p  NS). There was no evidence of stent malapposi-
ion, and most struts were covered by a neointima as
Characteristics
in 2 mg
Patients
Rapamycin 5 mg
n  30 Patients p Value
10.3 59.7  9.7 1.0
87) 25 (83) 0.72
20) 6 (20) 1.0
10) 0 (0) 0.24
13) 7 (23) 0.31
10) 4 (13) 0.69
0) 2 (7) 0.49
63) 21 (70) 0.58
93) 27 (93) 0.97
7) 1 (3) 1.0
20) 4 (13) 0.49
24) 7 (23) 0.94
63) 12 (40) 0.07
53) 11 (37) 0.19
0.10 0.51  0.06 0.21
29* n  30
28) 20 (66) 0.003
55) 8 (27) 0.03
17) 2 (7) 0.21
0.67 1.40  0.62 0.005
Lesions n  37 Lesions
43) 16 (43) 0.97
29) 5 (14) 0.10
29) 16 (43) 0.16
6.75 13.57  4.84 0.67
0.44 3.09  0.51 0.36
0.5 1.3  0.5 0.02
16) 2 (5) 0.18
41) 21 (57) 0.14
18) 3 (8) 0.17
25) 5 (14) 0.21
percutaneous coronary intervention.ural
amyc
30
9.7 
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12 (emonstrated by the neointimal volume in this cohort.
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October 6, 2004:1386–92 Results of the ORBIT Pilot Studyurther, not all patients were available for angiographic or
VUS follow-up; however, those who were unavailable were
symptomatic.
Subset analysis of patients (n  38) who had IVUS
ollow-up with multi- versus single-stent showed similar
orrected intimal hyperplasia volumes between these two
roups, respectively (2.27  0.93 vs. 2.08  1.3; p  0.7).
imilar subset analysis of late loss in patients with QCA (n
53) did not show any statistically significant difference
etween multi- versus single-stent cohorts (0.7 0.4 vs. 0.5
0.5; p  0.18). Within an individual patient with
ultiple stents (n  13), IVUS analysis showed a similar
mount of corrected intimal hyperplasia in each lesion
mean 2.26 vs. 2.07 mm3; p  0.60). The mean difference
f corrected intimal hyperplasia volume between each lesion
ithin an individual patient was 0.191 mm3.
ix-month clinical outcomes. Clinical follow-up at six
onths was available in 29 patients (96%) in the 2-mg
apamycin group and 30 patients (100%) in the 5-mg
apamycin cohort (Table 3). One patient did withdraw
rom the 2-mg cohort and was, therefore, unavailable for
Table 2. Angiographic Characteristics—Pre-Pr
Parameters
Rapamyci
n  49 L
(Pre and
n  42 Lesi
Minimal luminal diameter, mm
Pre 1.08
Post 2.88
Six-month F/U 2.29
Diameter stenosis, %
Pre 62.07
Post 13.12
Six-month F/U 21.53
Binary restenosis
In-stent 3/42 (7
In-lesion 2/42 (4
Late loss, mm
In-stent 0.60
In-lesion 0.60
F/U  follow-up.
Table 3. Major Clinical Events at Six Months
Rapamycin 2
n  29 Patie
Cardiac death, n (%) 0/29 (0%)
Non-cardiac death, n (%) 0/29 (0%)
Q-wave MI, n (%) 0/29 (0%)
Non–Q-wave MI, n (%) 3/29 (10.0%
MACE 7/29 (24%)
Repeat revascularization n  42 lesio
TVR, n (%) 7/42 (16.7%
TVR-CABG 4/42 (9.5%
TVR-PCI 3/42 (7.1%
TLR, n (%) 6/42 (14.3%
TLR-CABG 3/42 (7.1%
TLR-PCI 3/42 (7.1%
CABG  coronary bypass graft surgery; MACE  majo
percutaneous coronary intervention; TLR  target lesion revasculaix-month follow-up. There were no documented deaths,
-wave or non–Q-wave MIs beyond hospital discharge.
he rate of clinically driven TLR (defined as revasculariza-
ion at the target site associated with any of the following:
ositive functional ischemia study, ischemic symptoms, and
n angiographic minimum lumen diameter stenosis 50%
y QCA or revascularization of a target site with diameter
tenosis 70% by QCA without either angina or a positive
unctional study was 14.3% vs. 6.9%; p  0.33) and TVR
including CABG to non-restenotic vessels (16.7% vs.
0.6%; p  0.67) were similar in the two groups. The high
ate of TVR in this study was a result of patients who went
o CABG and had complete revascularization including
essels treated in the study that were non-restenotic at the
ime of the surgery. Overall, seven patients (three in 2-mg
nd four in 5-mg group) had CABG to nine target vessels
t six months. Although angiographic stenosis did not meet
he definition of binary restenosis, one patient in the 2-mg
roup and three in the 5-mg group had bypass grafts to
RBIT vessels at the time of CABG at the discretion of the
urgeons. These patients were referred to elective CABG
ural, Post-Intervention, and at Six Months
g
s
)
/U)
Rapamycin 5 mg
n  37 Lesions
(Pre and Post)
n  29 Lesions (F/U) p Value
1.36  0.52 0.033
2.95  0.52 0.683
2.27  0.75 0.781
55.5  15.34 0.063
9.54  5.38 0.010
22.72  23.72 0.935
2/29 (6.9%) 0.524
2/29 (6.9%) 0.897
0.71  0.49 0.582
0.68  0.56 0.783
Rapamycin 5 mg
n  30 Patients p Value
0/30 (0%) —
0/30 (0%) —
0/30 (0%) —
2/30 (6.7%) 0.61
6/30 (20.0%) 0.71
n  29 lesions
6/29 (20.6%) 0.67
5/29 (17.2%) 0.34
1/29 (3.4%) 0.51
2/29 (6.9%) 0.33
2/29 (6.9%) 0.97
0/29 (0%) 0.14
erse cardiac events; MI  myocardial infarction; PCI oced
n 2 m
esion
Post
ons (F
0.61
0.57
0.61
18.03
6.76
15.64
.1%)
.8%)
0.54
0.61mg
nts
)
ns
)
)
)
)
)
)
r adv
rization; TVR  target vessel revascularization.
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Results of the ORBIT Pilot Study October 6, 2004:1386–92ue to progression of disease in other vessels including one
eft main disease. Three patients in the 2-mg and one
atient in the 5-mg group had repeat PCI at six months. In
he 2-mg group, all three PCIs were TLRs, and in the 5-mg
roup it was TVR-PCI. The pattern of in-stent restenosis
as focal, diffuse, and total occlusion in each of the three
atients in the 2-mg group. These restenotic lesions were
reated with cutting balloon, repeat stenting to optimize the
esult, and brachytherapy in one patient. The patient in the
-mg group had no restenosis of the initial stent implanted
o right posterior descending artery, but a proximal lesion
rogressed that required PCI.
rug tolerance and side-effect profile. Tolerance of 2 mg
as better than 5 mg with 27 of 30 patients (90%)
ompleting four weeks of Rapamycin (26.7  7.8 days) in
he 2-mg group; however, one-third of the patients (10 of
0, 33%) in the 5-mg group did not complete the course (22
11.7 days) (p  0.06). Serum rapamycin levels at days 1
nd 30 are shown in Table 4. Side effects were reported in
3 of 30 patients (43.3%) in the 2-mg group and 20 of 30
66.7%) in the 5-mg group. More than one symptom was
eported in six patients in the 5-mg group (four patients had
wo symptoms each, and two patients had three symptoms
ach) and none in the 2-mg group. The symptoms were
lassified as: mild—probably drug-related, tolerated, and
Table 4. Laboratory Index at Baseline and 30
In-Hosp
Rapamycin
2 mg
Rapamycin level, ng/ml 5.2  3.1*
Total cholesterol, mg/dl 196  38
HDL, mg/dl 42  9
LDL, mg/dl 124  35
Triglyceride, mg/dl 158 92
*Serum level at day 1; †p  0.05 vs. 2 mg Rapamycin at 30
HDL  high-density lipoprotein; LDL  low-density l
Table 5. Report of Side Effects and Their Sev
Side Effect 2-mg Group (n
None, n (%) 17 (56.6)
Reported, n (%) 13 (43.3)
Individual Symptoms* Mild Moderate
Nausea 1 0
Vomiting 0 1
Diarrhea 3 1
Blood diarrhea 0 0
Gum sores 3 1
Rashes 1 1
Fatigue 0 0
Elevated triglycerides 0 0
Leucopenia 0 0
Hepatic dysfunction 0 0
Total, n (%)‡ 8 (61.5) 4 (30.7)
*Each side effect is counted separately in every patient; †Fo
symptoms each; ‡Percentages expressed in relation to total numbeontrolled with palliative therapy; moderate—definitely re-
ated to the drug, but not requiring discontinuation, higher
n intensity but controlled with palliative therapy; and
evere—definitely related to the drug and requiring discon-
inuation of the drug. The rates of mild and moderate
ymptoms were 61.5%, 30.7% in 2-mg group and 75%,
4.3% in 5-mg group, respectively. Severe symptoms were
eported in 7.6% and 10.7% in 2- and 5-mg groups,
espectively, which required withdrawal of the study drug.
n addition to the patients with severe symptoms, two other
atients in the 2-mg group and seven other patients in the
-mg group discontinued the drug before completing the
ourse. Table 5 shows the details of side effects reported. No
ignificant leucopenia was detected in either cohort at
0-day follow-up. Side effects resulting in Rapamycin dis-
ontinuation included rash, mouth ulcers, diarrhea, and
atigue. All side effects remitted with cessation of medica-
ion. Hypertriglyceridemia was evident, particularly in the
-mg Rapamycin group, without clinical consequences (Ta-
le 4). The increase in the triglycerides represents 17
atients who had more than a 20-U increase in their
riglycerides. Of these patients, 15 had lipid studies done
fter 30 days. All but one patient (baseline triglyceride level
f 93; 30-day triglyceride level of 158; 6-month triglyceride
evel of 155) returned to their pre-procedure triglyceride
30 Days
amycin
5 mg
Rapamycin
2 mg
Rapamycin
5 mg
 6.4* 6.4 4.2 18.7  12.7†
 36 170 34 201  40
 15 46 9 42  5
 43 91 32 118  38†
 72 185 131 236  105
tein.
Associated With the Study Medication
) 5-mg Group (n  30)
10 (33.3)
20 (66.7)†
Severity
Severe Mild Moderate Severe
0 0 0 0
0 1 0 0
0 5 0 1
1 0 0 0
0 3 2 1
0 9 1 0
0 0 1 0
0 0 0 1
0 2 0 0
0 1 0 0
1 (7.6) 21 (75.0) 4 (14.3) 3 (10.7)
ients had two symptoms each, and two patients had threeDays
ital
Rap
6.4
178
42
107
163
days.erity
 30
ur pat
r of symptoms in each group.
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October 6, 2004:1386–92 Results of the ORBIT Pilot Studyevels. Six-month follow-up suggested that there were no
linical consequences to the patients who presented with
ypertriglyceridemia. Body mass index did not have any
ignificant effect on restenosis, drug level at 30 days, or the
umber of patients experiencing side effects related to the
rug. Further, the blood levels of Rapamycin were not
orrelated to the rate of side effects (chi-square test for
rend: p  0.48).
ISCUSSION
he principal findings of this study include: 1) oral Rapa-
ycin administration is feasible for 30 days for restenosis
revention of de novo coronary lesions; 2) the current
osing strategies of 2 and 5 mg Rapamycin resulted in low
nd similar rates of six-month TLR and TVR; 3) no dose
esponse was seen in the two Rapamycin cohorts as evi-
enced by similar rates of late loss and IVUS percent
olume obstruction at six months; 4) hypertriglyceridemia
as seen predominantly in the 5-mg Rapamycin group
ithout clinical consequences; and 5) severe side effects
ttributable to rapamycin were infrequent.
Single-digit restenosis rates have been achieved with
apamycin-eluting stents (1–7). While the evidence for
ffectiveness of drug-eluting stents is mounting, their long-
erm durability and use for multivessel disease remain
nknown. Although locally delivered Rapamycin is the
ubject of intensive investigation, only one published study
as assessed oral Rapamycin therapy and found no clinical
enefit when administered to patients at high risk for
estenosis (23). This cohort of 15 patients had recalcitrant
n-stent restenosis that had either failed or were not candi-
ates for intracoronary radiation, a population markedly
ifferent from patients with de novo coronary lesions. Lack
f efficacy seen with oral Rapamycin in that study may have
een due to inadequate drug dosing (2 mg/day for 30 days).
urther, serum Rapamycin levels were not reported, and
here are no data to support the efficacy of Rapamycin-
luting stents for this subset of patients. It is possible that
atients with refractory restenosis, such as those who failed
adiation therapy, will not respond well to either eluting or
ral Rapamycin. In contrast, the Oral Sirolimus to Inhibit
ecurrent In-stent Stenosis (OSIRIS) (24) and Oral Rapa-
ycin to Prevent Restenosis in Patients Undergoing Cor-
nary Stent Therapy (ORAR) (25) trials showed beneficial
ffects in restenotic and de novo lesions, respectively.
The late loss reported in RAndomized study with the
irolimus-eluting VElocity balloon-expandable stent in the
reatment of patients with de novo native coronary artery
esions (RAVEL), SIRIUS, and TAXUS IV ranged from
0.01  0.33 mm to 0.39  0.5 mm with drug-eluting
tents and 0.80  0.53 mm to 1.0  0.7 mm with bare
etal stents (6,7). The late loss with oral Rapamycin (0.64
0.52 mm) in the present study was higher than that of
rug-eluting stents but was still lower than reported historic
ontrols of standard stent cohorts from these studies. This beduction in the late loss translated into low in-stent (7.1%
s. 6.9%; p  NS) and in-lesion (4.8% vs. 6.9%; p  NS)
inary restenosis rates for both 2-mg and 5-mg groups.
here were no early or late stent thromboses and no late
neurysms as expected.
In-stent restenosis and cardiac transplantation vasculopa-
hy are both characterized by intense intimal proliferation
econdary to SMC proliferation. Rapamycin targets central
egulators of cell cycle progression in vascular SMCs,
ncluding the cyclin-dependent kinase inhibitor p27kip1
21,22). Rapamycin combines anti-proliferative and anti-
igratory properties with immunosuppressant activity and
as been shown to prevent and treat graft (cardiac trans-
lant) vasculopathy (26). In an open-labeled study of 46
atients with graft vasculopathy, oral Rapamycin reduced
he number of primary end points (composite of death, MI,
eed for revascularization, or angiographic deterioration)
nd secondary end points (cardiac hospitalizations), with no
ncrease in rate of infection. This effect of rapamycin was
eemingly independent of its immunosuppression, implying
predominant anti-proliferative action (27). Our study
upports the feasibility of systemic Rapamycin therapy in
he prevention of neointimal proliferation.
To our knowledge, our study is among the first to report
f Rapamycin for restenosis prevention of de novo coronary
esions. This study has the inherent limitations of a single-
enter registry without a control group and a limited
ollow-up to six months. The lack of statistically significant
ndings in the study could be due to the small sample size.
urther, not all patients were available for angiographic and
VUS follow-up; however, those who were unavailable were
symptomatic.
Interestingly, for patients who completed four weeks of
apamycin treatment, dose levels did not have any effect on
estenosis outcome variables (chi-square test for trend: 2
g, p  0.57; 5 mg, p  0.64). Further, the duration of
apamycin for patients who withdrew from the drug before
he 30 days also did not affect restenosis (chi-square test for
rend: 2 mg, p  0.43; 5 mg, p  0.76). The cumulative
ose of Rapamycin did not have any significant effect on
estenosis (chi-square test for trend: p  0.36).
Thus, the study posed several questions relating to
ptimal and therapeutic loading doses as well as time and
uration of drug administration. The current dose used in
atients after renal transplantation is 2 mg/day, and it is
ossible that a dose of 5 mg is not necessary for the vascular
pplication, because no clinical and angiographic differences
ere detected between the 2- and 5-mg groups in the
resent study. Because dose levels and duration of treatment
id not have an effect on restenosis outcome variables,
erhaps it is the loading dose that can make the difference.
he OSIRIS study supports pretreatment, higher loading
oses, and short treatment times for patients with in-stent
estenosis. Implementation of this strategy may improve the
utcome of de novo lesions as well. It is also unclear whether
lood levels of the drug should be monitored. For renal
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Results of the ORBIT Pilot Study October 6, 2004:1386–92ransplant patients, a Rapamune level 8 g/ml is recom-
ended. The ORAR study did show beneficial effects when
lood levels were 8 g/ml. In the present study, we could
ot detect correlation between the Rapamune level and
linical events or late loss. Nevertheless, it is possible that
arger sample sizes would have detected optimal blood
evels. If so, this is a deficiency of this strategy, which would
nvolve extra costs and inconvenience.
Finally, the cost of 2 mg of oral rapamycin for 30 days is
early $500 per patient. This is significantly lower than the
urrent cost of drug-eluting stents. This difference is more
ronounced when multiple stents are required to treat
ultivessel disease. Another potential benefit of the drug is
ts anti-inflammatory properties, which may prove beneficial
n the setting of acute coronary syndrome in the vulnerable
atients.
onclusions. In this preliminary analysis, oral Rapamycin
dministration for the prevention of restenosis is safe and
easible. Lower rates of restenosis and later loss than
nticipated were observed in both dosing strategies (without
ose-response). The ORBIT II study, an international,
ulticenter, randomized trial, has been initiated and will
etermine whether systemic oral administration of Rapa-
ycin will be a therapeutic option for patients undergoing
CI.
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